MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jconrel.2024.12.052

Медицинская библиотека · Journal of controlled release : official journal of the Controlled Release Society · 2025

D-peptide hydrogels as a long-acting multipurpose drug delivery platform for combined contraception and HIV prevention.

Pentlavalli Sreekanth, Coulter Sophie M, An Yuming, Cross Emily R, Sun Han, Moore Jessica V, Sabri Akmal Bin, Greer Brett, Vora Lalitkumar, McCarthy Helen O, Laverty Garry

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

New multipurpose prevention technology products for use by women, focused on reducing HIV infection and preventing unwanted pregnancies, are a global health priority. Discreet long-acting formulations will empower women with greater choice around their sexual health. This paper outlines the development of a long-acting technology that enables multiple drugs to be incorporated within one injectable platform. This fixed-dose combination product is formed from a phosphorylated D-peptide (naphthalene-2-ly)-acetyl-diphenylalanine-lysine-tyrosine-glycine-OH (Napffky(p)G-OH) that enables the highly hydrophobic drugs MIV-150 (HIV antiretroviral) and etonogestrel (contraceptive) to be solubilized together within aqueous solvents. Upon subcutaneous injection, this D-peptide-drug combination self-assembles in response to phosphatase enzymes present within the skin space to form an in situ forming drug-releasing hydrogel depot. Oscillatory rheology confirmed the formation of hydrogels, which began within ∼10 s exposure to 3.98 U/mL phosphatase enzymes and continued for ∼198 mins for a Napffk(MIV-150)y(p)G-OH + Napffk(ENG)y(p)G-OH combination (8:2 ratio). Biostability against proteases, an important consideration for long-acting injectables, was demonstrated for at least 28 days in vitro. Covalent attachment of each drug to the D-peptide via an ester linkage enabled sustained release of the drug in an unmodified form via hydrolysis of the D-peptide-drug linker. This significantly reduced the initial drug burst. Low toxicity was also demonstrated in vitro via cell culture (MTS, LHS, Live/Dead®) and within in vivo studies (H&E staining). The fixed dose combination was able to deliver clinically relevant concentrations of each drug to Sprague-Dawley rats for at least 49 days, providing proof-of-concept for the use of hydrogel-forming D-peptides (Napffky(p)G-OH) as a long-acting injectable platform for the delivery of multiple hydrophobic drugs.

Для цитирования: Pentlavalli Sreekanth, Coulter Sophie M, An Yuming, Cross Emily R, Sun Han, Moore Jessica V, Sabri Akmal Bin, Greer Brett, Vora Lalitkumar, McCarthy Helen O, Laverty Garry. D-peptide hydrogels as a long-acting multipurpose drug delivery platform for combined contraception and HIV prevention.. Journal of controlled release : official journal of the Controlled Release Society. 2025. DOI: 10.1016/j.jconrel.2024.12.052.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.